Biobanking Market - A Global and Regional Analysis: Focus on Product and Service, Storage Type, Sample Type, Ownership, Biobank Type, Application, Country, and Region - Analysis and Forecast, 2025-2035
Biobanking refers to the process of collecting, storing, and managing biological samples (such as blood, tissue, DNA, RNA, and other bodily fluids) for research and medical purposes. These samples are preserved and catalogued in biorepositories or biobanks, where they are stored under controlled conditions to maintain their integrity for long-term use. Biobanks are invaluable resources for scientific research, particularly in fields like genomics, cancer research, drug development, and epidemiology.
Researchers use biobanks to investigate the genetic and environmental factors that contribute to diseases, understand disease mechanisms, and develop personalized treatments. Biobanks are also used for testing the efficacy of new medications, understanding population health trends, and advancing medical knowledge. With the growing focus on precision medicine, biobanks are becoming increasingly important as they provide high-quality biological samples that are essential for creating tailored healthcare solutions based on individual genetic profiles.
One of the key drivers of the biobanking market is the increasing demand for personalized medicine. As advancements in genomics and biotechnology continue to progress, there is a growing focus on tailoring medical treatments to individual patients based on their genetic makeup. Biobanks play a critical role in this area by storing diverse biological samples that can be used to understand genetic variations and their implications on health and disease. These samples help researchers develop targeted therapies and treatments that are more effective and less harmful to patients.
The rise in chronic diseases, such as cancer, diabetes, and cardiovascular conditions, further drives the need for biobanks. By providing a repository of biological materials, biobanks enable researchers to identify disease biomarkers, understand disease mechanisms, and develop new diagnostic and therapeutic methods. As personalized medicine becomes a central pillar of modern healthcare, the demand for biobanks and high-quality biological samples is expected to continue to grow.
Despite the growth of the biobanking market, several challenges persist. One of the primary challenges is the ethical and legal concerns associated with the collection, storage, and use of biological samples. Issues surrounding informed consent, privacy, and confidentiality of donor information remain a significant challenge. Ensuring that individuals provide informed consent for the use of their biological samples in research and that their privacy is protected is crucial, especially when dealing with sensitive genetic data.
Furthermore, the lack of uniform regulations and standardization in biobanking practices across different regions and institutions can lead to discrepancies in data quality, sample handling, and storage methods. This lack of standardization complicates data sharing and collaboration among research institutions, which can limit the global utility of biobank resources.
Lastly, there are financial, and infrastructure challenges related to maintaining biobanks, as they require significant investment in both the physical infrastructure (such as storage facilities) and technology to manage vast amounts of data and biological samples over extended periods.
The global Biobanking market is highly competitive, with major players such as Becton, Dickinson and Company, QIAGEN N.V., Merck KGaA, Thermo Fisher Scientific Inc., PHC Holdings Corporation, Cryoport, Inc., Azenta, Inc., Avantor, Inc., Tecan Trading AG, Greiner AG, Bay Biosciences LLC, Shanghai Zhangjiang Biobank, US Biolab Corporation, Inc., Cureline, and Brooks Life Sciences leading the way. These companies are continuously innovating and expanding their product portfolios to cater to the growing demand for biological sample storage, processing, and management in research, personalized medicine, and drug development.
The competition in the market is driven by advancements in technology, improvements in storage capabilities, and the increasing need for high-quality biological samples for clinical trials, genomic research, and disease study. With significant investments in infrastructure, digitalization, and regulatory compliance, these key players are well-positioned to shape the future of the biobanking market.
Biobanking Market Segmentation:
Segmentation 1: by Product and Service
Moreover, digital tools enable better tracking and management of samples across different research facilities and regions, promoting more efficient data sharing and collaboration between global biobank networks. With the growing demand for high-quality and well-organized biological samples, this trend is expected to continue to shape the biobanking industry, supporting advancements in personalized medicine, genomics, and drug development.
Researchers use biobanks to investigate the genetic and environmental factors that contribute to diseases, understand disease mechanisms, and develop personalized treatments. Biobanks are also used for testing the efficacy of new medications, understanding population health trends, and advancing medical knowledge. With the growing focus on precision medicine, biobanks are becoming increasingly important as they provide high-quality biological samples that are essential for creating tailored healthcare solutions based on individual genetic profiles.
One of the key drivers of the biobanking market is the increasing demand for personalized medicine. As advancements in genomics and biotechnology continue to progress, there is a growing focus on tailoring medical treatments to individual patients based on their genetic makeup. Biobanks play a critical role in this area by storing diverse biological samples that can be used to understand genetic variations and their implications on health and disease. These samples help researchers develop targeted therapies and treatments that are more effective and less harmful to patients.
The rise in chronic diseases, such as cancer, diabetes, and cardiovascular conditions, further drives the need for biobanks. By providing a repository of biological materials, biobanks enable researchers to identify disease biomarkers, understand disease mechanisms, and develop new diagnostic and therapeutic methods. As personalized medicine becomes a central pillar of modern healthcare, the demand for biobanks and high-quality biological samples is expected to continue to grow.
Despite the growth of the biobanking market, several challenges persist. One of the primary challenges is the ethical and legal concerns associated with the collection, storage, and use of biological samples. Issues surrounding informed consent, privacy, and confidentiality of donor information remain a significant challenge. Ensuring that individuals provide informed consent for the use of their biological samples in research and that their privacy is protected is crucial, especially when dealing with sensitive genetic data.
Furthermore, the lack of uniform regulations and standardization in biobanking practices across different regions and institutions can lead to discrepancies in data quality, sample handling, and storage methods. This lack of standardization complicates data sharing and collaboration among research institutions, which can limit the global utility of biobank resources.
Lastly, there are financial, and infrastructure challenges related to maintaining biobanks, as they require significant investment in both the physical infrastructure (such as storage facilities) and technology to manage vast amounts of data and biological samples over extended periods.
The global Biobanking market is highly competitive, with major players such as Becton, Dickinson and Company, QIAGEN N.V., Merck KGaA, Thermo Fisher Scientific Inc., PHC Holdings Corporation, Cryoport, Inc., Azenta, Inc., Avantor, Inc., Tecan Trading AG, Greiner AG, Bay Biosciences LLC, Shanghai Zhangjiang Biobank, US Biolab Corporation, Inc., Cureline, and Brooks Life Sciences leading the way. These companies are continuously innovating and expanding their product portfolios to cater to the growing demand for biological sample storage, processing, and management in research, personalized medicine, and drug development.
The competition in the market is driven by advancements in technology, improvements in storage capabilities, and the increasing need for high-quality biological samples for clinical trials, genomic research, and disease study. With significant investments in infrastructure, digitalization, and regulatory compliance, these key players are well-positioned to shape the future of the biobanking market.
Biobanking Market Segmentation:
Segmentation 1: by Product and Service
- Equipment
- Storage Equipment
- Sample Analysis Equipment
- Sample Processing Equipment
- Sample Transport Equipment
- Consumables
- Storage Consumables
- Analysis Consumables
- Processing Consumables
- Collection Consumables
- Services
- Storage Services
- Processing Services
- Transport Services
- Supply Services
- Software
- Manual Storage
- Automated Storage
- Blood Products
- Human Tissues
- Cell Lines
- Nucleic Acids
- Biological Fluids
- Human Waste Products
- Universities
- National/Regional Agencies
- Non-Profit Organizations
- Private Organizations
- Physical/Real Biobanks
- Tissue Biobanks
- Population-Based Biobanks
- Genetic (DNA/RNA)
- Disease-Based Biobanks
- Virtual Biobanks
- Regenerative Medicine
- Life Science Research
- Clinical Research
- Pharmaceutical & Biotechnology Companies and Cros
- Academic And Research Institutes
- Hospitals
- North America
- Europe
- Asia-Pacific
- Rest of the World
Moreover, digital tools enable better tracking and management of samples across different research facilities and regions, promoting more efficient data sharing and collaboration between global biobank networks. With the growing demand for high-quality and well-organized biological samples, this trend is expected to continue to shape the biobanking industry, supporting advancements in personalized medicine, genomics, and drug development.
Executive Summary
Scope and Definition
Market/Product Definition
Inclusion and Exclusion
Key Questions Answered
Analysis and Forecast Note
1. GLOBAL BIOBANKING MARKET: INDUSTRY OUTLOOK
1.1 Introduction
1.2 Market Trends
1.3 Regulatory Framework
1.4 Case Studies
1.5 Product Benchmarking
1.6 Market Dynamics
1.6.1 Impact Analysis
1.6.2 Market Drivers
1.6.3 Market Challenges
1.6.4 Market Opportunities
2. GLOBAL BIOBANKING MARKET (BY PRODUCT AND SERVICE), ($BILLION), 2024-2035
2.1 Equipment
2.1.1 Storage Equipment
2.1.2 Sample Analysis Equipment
2.1.3 Sample Processing Equipment
2.1.4 Sample Transport Equipment
2.2 Consumables
2.2.1 Storage Consumables
2.2.2 Analysis Consumables
2.2.3 Processing Consumables
2.2.4 Collection Consumables
2.3 Services
2.3.1 Storage Services
2.3.2 Processing Services
2.3.3 Transport Services
2.3.4 Supply Services
2.4 Software
3. GLOBAL BIOBANKING MARKET (BY STORAGE TYPE), ($BILLION), 2024-2035
3.1 Manual Storage
3.2 Automated Storage
4. GLOBAL BIOBANKING MARKET (BY SAMPLE TYPE), ($BILLION), 2024-2035
4.1 Blood Products
4.2 Human Tissues
4.3 Cell Lines
4.4 Nucleic Acids
4.5 Biological Fluids
4.6 Human Waste Products
5. GLOBAL BIOBANKING MARKET (BY OWNERSHIP), ($BILLION), 2024-2035
5.1 Universities
5.2 National/Regional Agencies
5.3 Non-Profit Organizations
5.4 Private Organizations
6. GLOBAL BIOBANKING MARKET (BY BIOBANK TYPE), ($BILLION), 2024-2035
6.1 Physical/Real Biobanks
6.2 Tissue Biobanks
6.3 Population-Based Biobanks
6.4 Genetic (DNA/RNA)
6.5 Disease-Based Biobanks
6.6 Virtual Biobanks
7. GLOBAL BIOBANKING MARKET (BY APPLICATION), ($BILLION), 2024-2035
7.1 Regenerative Medicine
7.2 Life Science Research
7.3 Clinical Research
8. GLOBAL BIOBANKING MARKET (BY END USER), ($BILLION), 2024-2035
8.1 Pharmaceutical & Biotechnology Companies and Cros
8.2 Academic And Research Institutes
8.3 Hospitals
9. GLOBAL BIOBANKING MARKET (BY REGION), ($BILLION), 2024-2035
9.1 North America
9.1.1 Key Findings
9.1.2 Market Dynamics
9.1.3 Market Sizing and Forecast
9.1.3.1 North America Biobanking Market, by Country
9.1.3.1.1 U.S.
9.1.3.1.2 Canada
9.2 Europe
9.2.1 Key Findings
9.2.2 Market Dynamics
9.2.3 Market Sizing and Forecast
9.2.3.1 Europe Biobanking Market, by Country
9.2.3.1.1 Germany
9.2.3.1.2 U.K.
9.2.3.1.3 France
9.2.3.1.4 Italy
9.2.3.1.5 Spain
9.2.3.1.6 Rest of the Europe
9.3 Asia Pacific
9.3.1 Key Findings
9.3.2 Market Dynamics
9.3.3 Market Sizing and Forecast
9.3.3.1 Asia Pacific Biobanking Market, by Country
9.3.3.1.1 China
9.3.3.1.2 Japan
9.3.3.1.3 India
9.3.3.1.4 Australia
9.3.3.1.5 Rest of Asia Pacific
9.4 Rest of the World
9.4.1 Key Findings
9.4.2 Market Dynamics
9.4.3 Market Sizing and Forecast
10. GLOBAL BIOBANKING MARKET: COMPETITIVE LANDSCAPE AND COMPANY PROFILES
10.1 Key Strategies and Development
10.1.1 Mergers and Acquisitions
10.1.2 Synergistic Activities
10.1.3 Business Expansions and Funding
10.1.4 Product Launches and Approvals
10.1.5 Other Activities
10.2 Company Profiles
10.2.1 Becton, Dickinson and Company
10.2.1.1 Overview
10.2.1.2 Top Products / Product Portfolio
10.2.1.3 Top Competitors
10.2.1.4 Target Customers/End-Users
10.2.1.5 Key Personnel
10.2.1.6 Analyst View
10.2.2 QIAGEN N.V.
10.2.2.1 Overview
10.2.2.2 Top Products / Product Portfolio
10.2.2.3 Top Competitors
10.2.2.4 Target Customers/End-Users
10.2.2.5 Key Personnel
10.2.2.6 Analyst View
10.2.3 Merck KGaA
10.2.3.1 Overview
10.2.3.2 Top Products / Product Portfolio
10.2.3.3 Top Competitors
10.2.3.4 Target Customers/End-Users
10.2.3.5 Key Personnel
10.2.3.6 Analyst View
10.2.4 Thermo Fisher Scientific Inc.
10.2.4.1 Overview
10.2.4.2 Top Products / Product Portfolio
10.2.4.3 Top Competitors
10.2.4.4 Target Customers/End-Users
10.2.4.5 Key Personnel
10.2.4.6 Analyst View
10.2.5 PHC Holdings Corporation
10.2.5.1 Overview
10.2.5.2 Top Products / Product Portfolio
10.2.5.3 Top Competitors
10.2.5.4 Target Customers/End-Users
10.2.5.5 Key Personnel
10.2.5.6 Analyst View
10.2.6 Cryoport, Inc.
10.2.6.1 Overview
10.2.6.2 Top Products / Product Portfolio
10.2.6.3 Top Competitors
10.2.6.4 Target Customers/End-Users
10.2.6.5 Key Personnel
10.2.6.6 Analyst View
10.2.7 Azenta, Inc.
10.2.7.1 Overview
10.2.7.2 Top Products / Product Portfolio
10.2.7.3 Top Competitors
10.2.7.4 Target Customers/End-Users
10.2.7.5 Key Personnel
10.2.7.6 Analyst View
10.2.8 Avantor, Inc.
10.2.8.1 Overview
10.2.8.2 Top Products / Product Portfolio
10.2.8.3 Top Competitors
10.2.8.4 Target Customers/End-Users
10.2.8.5 Key Personnel
10.2.8.6 Analyst View
10.2.9 Tecan Trading AG
10.2.9.1 Overview
10.2.9.2 Top Products / Product Portfolio
10.2.9.3 Top Competitors
10.2.9.4 Target Customers/End-Users
10.2.9.5 Key Personnel
10.2.9.6 Analyst View
10.2.10 Greiner AG
10.2.10.1 Overview
10.2.10.2 Top Products / Product Portfolio
10.2.10.3 Top Competitors
10.2.10.4 Target Customers/End-Users
10.2.10.5 Key Personnel
10.2.10.6 Analyst View
10.2.11 Bay Biosciences LLC
10.2.11.1 Overview
10.2.11.2 Top Products / Product Portfolio
10.2.11.3 Top Competitors
10.2.11.4 Target Customers/End-Users
10.2.11.5 Key Personnel
10.2.11.6 Analyst View
10.2.12 Shanghai Zhangjiang Biobank
10.2.12.1 Overview
10.2.12.2 Top Products / Product Portfolio
10.2.12.3 Top Competitors
10.2.12.4 Target Customers/End-Users
10.2.12.5 Key Personnel
10.2.12.6 Analyst View
10.2.13 US Biolab Corporation, Inc.
10.2.13.1 Overview
10.2.13.2 Top Products / Product Portfolio
10.2.13.3 Top Competitors
10.2.13.4 Target Customers/End-Users
10.2.13.5 Key Personnel
10.2.13.6 Analyst View
10.2.14 Cureline
10.2.14.1 Overview
10.2.14.2 Top Products / Product Portfolio
10.2.14.3 Top Competitors
10.2.14.4 Target Customers/End-Users
10.2.14.5 Key Personnel
10.2.14.6 Analyst View
10.2.15 Brooks Life Sciences
10.2.15.1 Overview
10.2.15.2 Top Products / Product Portfolio
10.2.15.3 Top Competitors
10.2.15.4 Target Customers/End-Users
10.2.15.5 Key Personnel
10.2.15.6 Analyst View
11. RESEARCH METHODOLOGY
Scope and Definition
Market/Product Definition
Inclusion and Exclusion
Key Questions Answered
Analysis and Forecast Note
1. GLOBAL BIOBANKING MARKET: INDUSTRY OUTLOOK
1.1 Introduction
1.2 Market Trends
1.3 Regulatory Framework
1.4 Case Studies
1.5 Product Benchmarking
1.6 Market Dynamics
1.6.1 Impact Analysis
1.6.2 Market Drivers
1.6.3 Market Challenges
1.6.4 Market Opportunities
2. GLOBAL BIOBANKING MARKET (BY PRODUCT AND SERVICE), ($BILLION), 2024-2035
2.1 Equipment
2.1.1 Storage Equipment
2.1.2 Sample Analysis Equipment
2.1.3 Sample Processing Equipment
2.1.4 Sample Transport Equipment
2.2 Consumables
2.2.1 Storage Consumables
2.2.2 Analysis Consumables
2.2.3 Processing Consumables
2.2.4 Collection Consumables
2.3 Services
2.3.1 Storage Services
2.3.2 Processing Services
2.3.3 Transport Services
2.3.4 Supply Services
2.4 Software
3. GLOBAL BIOBANKING MARKET (BY STORAGE TYPE), ($BILLION), 2024-2035
3.1 Manual Storage
3.2 Automated Storage
4. GLOBAL BIOBANKING MARKET (BY SAMPLE TYPE), ($BILLION), 2024-2035
4.1 Blood Products
4.2 Human Tissues
4.3 Cell Lines
4.4 Nucleic Acids
4.5 Biological Fluids
4.6 Human Waste Products
5. GLOBAL BIOBANKING MARKET (BY OWNERSHIP), ($BILLION), 2024-2035
5.1 Universities
5.2 National/Regional Agencies
5.3 Non-Profit Organizations
5.4 Private Organizations
6. GLOBAL BIOBANKING MARKET (BY BIOBANK TYPE), ($BILLION), 2024-2035
6.1 Physical/Real Biobanks
6.2 Tissue Biobanks
6.3 Population-Based Biobanks
6.4 Genetic (DNA/RNA)
6.5 Disease-Based Biobanks
6.6 Virtual Biobanks
7. GLOBAL BIOBANKING MARKET (BY APPLICATION), ($BILLION), 2024-2035
7.1 Regenerative Medicine
7.2 Life Science Research
7.3 Clinical Research
8. GLOBAL BIOBANKING MARKET (BY END USER), ($BILLION), 2024-2035
8.1 Pharmaceutical & Biotechnology Companies and Cros
8.2 Academic And Research Institutes
8.3 Hospitals
9. GLOBAL BIOBANKING MARKET (BY REGION), ($BILLION), 2024-2035
9.1 North America
9.1.1 Key Findings
9.1.2 Market Dynamics
9.1.3 Market Sizing and Forecast
9.1.3.1 North America Biobanking Market, by Country
9.1.3.1.1 U.S.
9.1.3.1.2 Canada
9.2 Europe
9.2.1 Key Findings
9.2.2 Market Dynamics
9.2.3 Market Sizing and Forecast
9.2.3.1 Europe Biobanking Market, by Country
9.2.3.1.1 Germany
9.2.3.1.2 U.K.
9.2.3.1.3 France
9.2.3.1.4 Italy
9.2.3.1.5 Spain
9.2.3.1.6 Rest of the Europe
9.3 Asia Pacific
9.3.1 Key Findings
9.3.2 Market Dynamics
9.3.3 Market Sizing and Forecast
9.3.3.1 Asia Pacific Biobanking Market, by Country
9.3.3.1.1 China
9.3.3.1.2 Japan
9.3.3.1.3 India
9.3.3.1.4 Australia
9.3.3.1.5 Rest of Asia Pacific
9.4 Rest of the World
9.4.1 Key Findings
9.4.2 Market Dynamics
9.4.3 Market Sizing and Forecast
10. GLOBAL BIOBANKING MARKET: COMPETITIVE LANDSCAPE AND COMPANY PROFILES
10.1 Key Strategies and Development
10.1.1 Mergers and Acquisitions
10.1.2 Synergistic Activities
10.1.3 Business Expansions and Funding
10.1.4 Product Launches and Approvals
10.1.5 Other Activities
10.2 Company Profiles
10.2.1 Becton, Dickinson and Company
10.2.1.1 Overview
10.2.1.2 Top Products / Product Portfolio
10.2.1.3 Top Competitors
10.2.1.4 Target Customers/End-Users
10.2.1.5 Key Personnel
10.2.1.6 Analyst View
10.2.2 QIAGEN N.V.
10.2.2.1 Overview
10.2.2.2 Top Products / Product Portfolio
10.2.2.3 Top Competitors
10.2.2.4 Target Customers/End-Users
10.2.2.5 Key Personnel
10.2.2.6 Analyst View
10.2.3 Merck KGaA
10.2.3.1 Overview
10.2.3.2 Top Products / Product Portfolio
10.2.3.3 Top Competitors
10.2.3.4 Target Customers/End-Users
10.2.3.5 Key Personnel
10.2.3.6 Analyst View
10.2.4 Thermo Fisher Scientific Inc.
10.2.4.1 Overview
10.2.4.2 Top Products / Product Portfolio
10.2.4.3 Top Competitors
10.2.4.4 Target Customers/End-Users
10.2.4.5 Key Personnel
10.2.4.6 Analyst View
10.2.5 PHC Holdings Corporation
10.2.5.1 Overview
10.2.5.2 Top Products / Product Portfolio
10.2.5.3 Top Competitors
10.2.5.4 Target Customers/End-Users
10.2.5.5 Key Personnel
10.2.5.6 Analyst View
10.2.6 Cryoport, Inc.
10.2.6.1 Overview
10.2.6.2 Top Products / Product Portfolio
10.2.6.3 Top Competitors
10.2.6.4 Target Customers/End-Users
10.2.6.5 Key Personnel
10.2.6.6 Analyst View
10.2.7 Azenta, Inc.
10.2.7.1 Overview
10.2.7.2 Top Products / Product Portfolio
10.2.7.3 Top Competitors
10.2.7.4 Target Customers/End-Users
10.2.7.5 Key Personnel
10.2.7.6 Analyst View
10.2.8 Avantor, Inc.
10.2.8.1 Overview
10.2.8.2 Top Products / Product Portfolio
10.2.8.3 Top Competitors
10.2.8.4 Target Customers/End-Users
10.2.8.5 Key Personnel
10.2.8.6 Analyst View
10.2.9 Tecan Trading AG
10.2.9.1 Overview
10.2.9.2 Top Products / Product Portfolio
10.2.9.3 Top Competitors
10.2.9.4 Target Customers/End-Users
10.2.9.5 Key Personnel
10.2.9.6 Analyst View
10.2.10 Greiner AG
10.2.10.1 Overview
10.2.10.2 Top Products / Product Portfolio
10.2.10.3 Top Competitors
10.2.10.4 Target Customers/End-Users
10.2.10.5 Key Personnel
10.2.10.6 Analyst View
10.2.11 Bay Biosciences LLC
10.2.11.1 Overview
10.2.11.2 Top Products / Product Portfolio
10.2.11.3 Top Competitors
10.2.11.4 Target Customers/End-Users
10.2.11.5 Key Personnel
10.2.11.6 Analyst View
10.2.12 Shanghai Zhangjiang Biobank
10.2.12.1 Overview
10.2.12.2 Top Products / Product Portfolio
10.2.12.3 Top Competitors
10.2.12.4 Target Customers/End-Users
10.2.12.5 Key Personnel
10.2.12.6 Analyst View
10.2.13 US Biolab Corporation, Inc.
10.2.13.1 Overview
10.2.13.2 Top Products / Product Portfolio
10.2.13.3 Top Competitors
10.2.13.4 Target Customers/End-Users
10.2.13.5 Key Personnel
10.2.13.6 Analyst View
10.2.14 Cureline
10.2.14.1 Overview
10.2.14.2 Top Products / Product Portfolio
10.2.14.3 Top Competitors
10.2.14.4 Target Customers/End-Users
10.2.14.5 Key Personnel
10.2.14.6 Analyst View
10.2.15 Brooks Life Sciences
10.2.15.1 Overview
10.2.15.2 Top Products / Product Portfolio
10.2.15.3 Top Competitors
10.2.15.4 Target Customers/End-Users
10.2.15.5 Key Personnel
10.2.15.6 Analyst View
11. RESEARCH METHODOLOGY
LIST OF FIGURES
Figure: Global Biobanking Market (by Product and Service), $Billion, 2024 and 2035
Figure: Global Biobanking Market (by Storage Type), $Billion, 2024 and 2035
Figure: Global Biobanking Market (by Sample Type), $Billion, 2024 and 2035
Figure: Global Biobanking Market (by Ownership), $Billion, 2024 and 2035
Figure: Global Biobanking Market (by Biobank Type), $Billion, 2024 and 2035
Figure: Global Biobanking Market (by Application), $Billion, 2024 and 2035
Figure: Global Biobanking Market (by End User), $Billion, 2024 and 2035
Figure: Global Biobanking Market (by Region), $Billion, 2024 and 2035
Figure: Global Biobanking Market Key Trends, Analysis
Figure: Global Biobanking Market (by Product and Service), $Billion, 2024 and 2035
Figure: Global Biobanking Market (by Storage Type), $Billion, 2024 and 2035
Figure: Global Biobanking Market (by Sample Type), $Billion, 2024 and 2035
Figure: Global Biobanking Market (by Ownership), $Billion, 2024 and 2035
Figure: Global Biobanking Market (by Biobank Type), $Billion, 2024 and 2035
Figure: Global Biobanking Market (by Application), $Billion, 2024 and 2035
Figure: Global Biobanking Market (by End User), $Billion, 2024 and 2035
Figure: Global Biobanking Market (by Region), $Billion, 2024 and 2035
Figure: Global Biobanking Market Key Trends, Analysis
LIST OF TABLES
Table: Global Biobanking Market Dynamics, Impact Analysis
Table: Global Biobanking Market (by Region), $Billion, 2024-2035
Table: Global Biobanking Market Dynamics, Impact Analysis
Table: Global Biobanking Market (by Region), $Billion, 2024-2035
